Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... what they believe is the thinnest-possible semiconductor, a ... only three atoms thick. , The University of ... single-layer semiconductor materials can be connected in an ... result could be the basis for next-generation flexible ... and solar technologies. , "Heterojunctions are fundamental elements ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis by ... of all Mers CoV virus strains has ... back to 2012.  This conservation and sharing of specific ... Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for the ... both of which have been found to be effective ...
(Date:8/26/2014)... added to the growing case for graphene being ... thing in the high-tech world by the two-dimensional ... of researchers led by a scientist with the ... Laboratory (Berkeley Lab) has reported the first experimental ... materials. The recorded charge transfer time clocked in ...
(Date:8/26/2014)... Ga. , Aug. 26, 2014  ViveBio, ... biological sample collection, stabilization and transportation, announced today ... Laboratory Procurement Services, LLC (LPS) of ... of products in the United States ... new class of ambient temperature dried biological specimen ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... ANGELES, Oct. 20 The Cure Our Children ... today,that the U.S. Food and Drug Administration (FDA) ... unique drug product for children with,Ewing,s Sarcoma cancer. ... possible,by the generous volunteers and researchers in private ...
... Oct. 20 On Wednesday, October,22, 2008, GlaxoSmithKline plc ... results for the three months ended September 30, 2008. ... Exchange at,approximately 12:00pm UK, 7:00 am EDT., At ... global teleconference,for analysts and investors, hosted by Andrew Witty, ...
... Oct. 20 Sustainable Oils has named ... as the company,s general manager. Scott Johnson ... to build camelina,production and marketing opportunities for ... joined the company on Oct. 1., ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 3Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 4
(Date:8/27/2014)... /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and Biology ... International Conference (EMBC,14), this year being held at the ... Illinois , from Tuesday, August 26 through Saturday, ... industry professionals in science, medicine, and engineering are registered ... This year,s conference theme is ...
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... the first human clinical trial of a recombinant vaccine ... ?and the results indicate the vaccine is safe and ... Center researchers report. , The nearly year-long pilot study ... each group received a series of three injections of ...
... Medical Center have uncovered part of the genetic mechanism that ... , A team led by SFVAMC vascular surgeon Rajabrata Sarkar, ... is essential for the growth of new arteries when the ... identified and described, for the first time, the specific DNA ...
... Brookhaven National Laboratory have just launched a web-based 3-D ... a popular laboratory mouse (see http://www.bnl.gov/CTN/mouse/ ). ... extremely accurate anatomical templates and use them to map ... brain are metabolically active and where particular genes are ...
Cached Biology News:Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 2Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 3Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 4Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
ANTI S. ENT TOX BC2D...
Porcine Serum US Origin 6 Months or Older...
... PlusOne Silver Staining Kit, Protein, ... Heukeshoven and Dernick (1), the kit ... gel electrophoresis systems.Silver Staining Kit, Protein ... of proteins in polyacrylamide gels in ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: